NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
This NIH SBIR Phase IIB award is restricted to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award; it bridges the gap between Phase II and commercializati…
- Deadline
- Apr 5, 2029
- Posted
- May 28, 2026
- Award amount
- Amount not specified
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Apr 5, 2029 so you have time to apply.
In plain English
This NIH SBIR Phase IIB award is restricted to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award; it bridges the gap between Phase II and commercialization for later-stage R&D. Only one such award is allowed per project, and applications must be submitted within the first six due dates after the Phase II budget period ends, so it is narrow and limited to existing grantees. Foreign organizations are not eligible to apply.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Only United States small business concerns (SBCs) that have previously received an NIH SBIR or STTR Phase II award are eligible to submit applications for this opportunity. Only one NIH Phase IIB Strategic Breakthrough award is allowed per project. This NOFO supports Renewal/Resubmission "Type 2" Applications from recipients with NIH Phase II SBIR/STTR awards that are submitted within the first six due dates following the expiration of their budget period. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Unfunded international collaborations or unfunded foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
About this grant
The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
National Institutes of Health · Amount varies · Due in 17 days
Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
National Institutes of Health · Amount varies · Due in 28 days
NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)
National Institutes of Health · Amount varies · Due in 28 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.